Bimekizumab versus Ustekinumab Efficacy Across Subgroups of Patients with Moderate to Severe Plaque Psoriasis: Results from the Multicenter, Randomized, Double-Blinded Phase 3 BE VIVID Trial

Main Article Content

B Strober
JG Krueger
N Magnolo
R Vender
DP Toth
D Thaci
M Wang
C Cioffi
C Madden
RB Warren

Keywords

Plaque Psoriasis, Bimekizumab, IL-17A, IL-17F, Ustekinumab

Abstract

Abstract not available.

References

1. Durham L. Curr Rheumatol Reports 2015;17:55

2. Fujishima S. Arch Dermatol Res 2010;302:499–505

3. Glatt S. Br J Clin Pharmacol 2017;83:991–1001

4. Papp KA. J Am Acad Dermatol 2018;79:277–86.e10

5. Kamiya K. Int J Mol Sci 2019;20:4347.